ibandronic acid has been researched along with cholecalciferol in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bergman, G; Gaugris, S; Jansen, JP; Sen, SS | 1 |
| Klaus, J; König, HH; Konnopka, A; Kreck, S; Leidl, R; Matschinger, H; von Tirpitz, C | 1 |
| Dimai, HP; Dobnig, H; Fahrleitner-Pammer, A; Hauge, E; Obermayer-Pietsch, BM; Pieber, TR; Pilz, S; Piswanger-Soelkner, JC; Portugaller, RH; Prenner, G; Tscheliessnigg, KH | 1 |
| Adler, G; Herdt, K; Klaus, J; Reinshagen, M; Schröter, C; von Boyen, GB; von Tirpitz, C | 1 |
| Adler, G; Herdt, K; Klaus, J; Reinshagen, M; von Boyen, GB; von Tirpitz, C | 1 |
| Hommann, M; Kaemmerer, D; Lehmann, G; Schmidt, B; Settmacher, U; Wolf, G | 1 |
| Brzeziańska, E; Cegłowska, A; Liberski, PP; Rieske, P; Sewerynek, E; Stêpień-Kłos, W; Stuss, M | 1 |
| Chae, SW; Im, YJ; Jeon, JY; Jun, H; Kim, EY; Kim, MG; Kim, Y; Lee, JW; Lee, SY; Lee, TW; Park, TS | 1 |
| Ohashi, S; Ono, K; Tanaka, S | 1 |
| Shiraishi, A | 1 |
| Yalla, N | 1 |
2 review(s) available for ibandronic acid and cholecalciferol
| Article | Year |
|---|---|
[Anti-osteoporosis drugs based on the guidelines for the Prevention and Treatment of Osteoporosis (2011 edition) ].
Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Cholecalciferol; Denosumab; Diphosphonates; Drug Therapy, Combination; Fractures, Spontaneous; Humans; Ibandronic Acid; Molecular Targeted Therapy; Osteoporosis; Practice Guidelines as Topic; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures; Teriparatide | 2014 |
[Pharmacological profile and clinical evidence in patients with primary osteoporosis treated with intravenous ibandronate].
Topics: Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Cholecalciferol; Diphosphonates; Disease Models, Animal; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Durapatite; Haplorhini; Humans; Ibandronic Acid; Infusions, Intravenous; Osteoporosis; Randomized Controlled Trials as Topic; Rats; Spinal Fractures | 2014 |
5 trial(s) available for ibandronic acid and cholecalciferol
| Article | Year |
|---|---|
Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial.
Topics: Acid Phosphatase; Adult; Antacids; Biomarkers; Bone Density Conservation Agents; Bone Resorption; Calcium Carbonate; Cholecalciferol; Collagen Type I; Diphosphonates; Double-Blind Method; Heart Transplantation; Humans; Ibandronic Acid; Isoenzymes; Lumbar Vertebrae; Male; Middle Aged; Radiography; Spinal Fractures; Tartrate-Resistant Acid Phosphatase; Time Factors; Transplantation, Homologous | 2009 |
Bones and Crohn's: no benefit of adding sodium fluoride or ibandronate to calcium and vitamin D.
Topics: Absorptiometry, Photon; Adult; Bone Density; Bone Density Conservation Agents; Calcium Citrate; Cholecalciferol; Crohn Disease; Diphosphonates; Female; Fractures, Bone; Humans; Ibandronic Acid; Male; Middle Aged; Sodium Fluoride; Vitamin D; Young Adult | 2011 |
Intravenous ibandronate or sodium-fluoride--a 3.5 years study on bone density and fractures in Crohn's disease patients with osteoporosis.
Topics: Absorptiometry, Photon; Adult; Bone Density; Bone Density Conservation Agents; Calcium Citrate; Cholecalciferol; Crohn Disease; Delayed-Action Preparations; Diphosphonates; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Ibandronic Acid; Incidence; Injections, Intravenous; Male; Middle Aged; Osteoporosis; Prevalence; Sodium Fluoride; Spinal Fractures; Treatment Outcome; Young Adult | 2011 |
Assessment of OPG/RANK/RANKL gene expression levels in peripheral blood mononuclear cells (PBMC) after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Calcium, Dietary; Cholecalciferol; Combined Modality Therapy; Dietary Supplements; Diphosphonates; Female; Gene Expression Regulation; Humans; Ibandronic Acid; Leukocytes, Mononuclear; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Osteoprotegerin; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; RNA, Messenger; Thiophenes | 2013 |
Comparison of the pharmacokinetics, safety, and tolerability of vitamin D3 in DP-R206 (150-mg ibandronate/24,000-IU vitamin D3 tablet) and as monotherapy (24,000 iu) in healthy male Korean adults.
Topics: Adult; Bone Density Conservation Agents; Chemistry, Pharmaceutical; Cholecalciferol; Cross-Over Studies; Diphosphonates; Drug Combinations; Humans; Ibandronic Acid; Male; Middle Aged; Republic of Korea; Tablets; Therapeutic Equivalency; Young Adult | 2014 |
4 other study(ies) available for ibandronic acid and cholecalciferol
| Article | Year |
|---|---|
Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cholecalciferol; Cost-Benefit Analysis; Diphosphonates; Drug Combinations; Drug Costs; Female; Fractures, Bone; Humans; Ibandronic Acid; Middle Aged; Models, Economic; Netherlands; Osteoporosis; Patient Compliance; Patient Simulation; Quality-Adjusted Life Years; United Kingdom | 2008 |
Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model.
Topics: Adult; Aged; Bone Density; Bone Density Conservation Agents; Calcium; Cholecalciferol; Cost-Benefit Analysis; Diphosphonates; Drug Therapy, Combination; Female; Fractures, Bone; Germany; Humans; Ibandronic Acid; Inflammatory Bowel Diseases; Male; Markov Chains; Models, Economic; Osteoporosis; Quality-Adjusted Life Years; Sodium Fluoride | 2008 |
Monthly ibandronate for the prevention of bone loss in patients after liver transplantation.
Topics: Absorptiometry, Photon; Administration, Oral; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Chi-Square Distribution; Cholecalciferol; Creatinine; Dietary Supplements; Diphosphonates; Drug Administration Schedule; Femur Neck; Fractures, Bone; Germany; Humans; Ibandronic Acid; Liver Transplantation; Lumbar Vertebrae; Osteoporosis; Prospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2012 |
Bad Breaks.
Topics: Bone Density Conservation Agents; Calcium Citrate; Cholecalciferol; Female; Fractures, Bone; Humans; Hypocalcemia; Ibandronic Acid; Middle Aged; Osteoporosis; Pubic Bone; Sacrum; Vitamin D Deficiency | 2018 |